Sarepta told RBC patient death confirmed unrelated to Elevidys
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am ...
Roche’s Muscle-Wasting Treatment Shows Positive Results in Late-Stage Trial
The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.